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tion of renal replacement therapy, cardiac performance tory hypertrophy is the major long-time evolutionary
pattern” and that “intervention beyond one year maymay change as a function of PTH level but not as the
be relatively ineffective.”effect of duration of therapy. Such a possibility is sug-
The fact that better results were obtained with perito-gested by the data presented in Table 3. Results given
neal dialysis may simply be due to better volume controlin the second and third columns show that cardiac mass,
in those patients. Other studies [2] have shown that thisvolume and function indexes deteriorate in some pa-
is not always the case. The absence of a relationship withtients but improve or do not change in others. The differ-
blood pressure could be related to the confounding effectences may depend on mode of dialysis and PTH concen-
of antihypertensive drugs, but probably also to an inde-tration.
pendent effect of volume retention.Therapy with EPO leads to the regression of LVH in
We recently showed [3] that prolonged strict volumedialysis patients. The mean hemoglobin level in the study
control can cause regression of dilatation and hypertro-group presented in the first column of Table 4 is 8.6 g/dl
phy of the left ventricle while abolishing the need for(range, 8.1–9.2), but the data plotted in Figure 1 reveal
antihypertensive drugs. An extreme example of a patientthat as many as 9 HD patients had a hemoglobin level
in whom volume control caused complete regression ofbelow 8 g/dl. We are curious as to whether these patients,
severe cardiomyopathy without hypertension [4] illus-particularly those with hemoglobin levels of 6–7 g/dl,
trates the importance of hypervolemia as an independentwere given EPO. If yes, it should be mentioned, because
risk factor. Clearly (as Foley et al stressed in earlierthis hormone affects cardiac function regardless of renal
publications) only intervention studies can definitely re-replacement therapy. If EPO was not given to these
solve the complicated problems of dialysis morbidity.patients, one wonders why the authors did not address
the severe anemia. Hu¨seyin To¨z, Mehmet O¨zkahya,
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To the Editor: We would like to thank all the corre-
spondents for their interest and helpful queries and com-
To the Editor: We would like to comment on the study ments.
of Foley et al [1]. In our opinion it is not correct to speak Dr. Erturk makes several reasonable points. It cer-
about the “natural history of cardiomyopathy” because tainly would have been of interest to look at the potential
the development of this cardiomyopathy is highly depen- role of post-dialysis blood pressures in the hemodialysis
dent on the way patients are treated, particularly the patients. The short answer is that we did not record
extent to which the treating team succeeds in controlling them, partly reflecting the fact that the study began in
“volume.” the early 1980s. It is hardly fair to say that post-dialysis
The fatalistic attitude that unfortunately prevails in blood pressure is a better predictor of LV mass index
many dialysis centres is supported by the conclusion that than pre-dialysis blood pressure. We have previously
shown, in a prospective cohort study of over a thousand“progressive left ventricular dilatation with compensa-
